Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Jury Hits J&J With $8 Billion Verdict

share with twitter share with LinkedIn share with facebook
share via e-mail
10/09/2019 | 02:49am EDT

Complainant claimed that use of Risperdal as child caused breast enlargement

By Peter Loftus 

A Philadelphia jury on Tuesday ordered Johnson & Johnson to pay $8 billion in damages to a Maryland man who said his use of J&J's antipsychotic Risperdal as a child caused enlarged breasts and the company failed to properly warn of this risk.

It was the biggest award to date among more than 13,000 lawsuits against J&J alleging that Risperdal caused a condition called gynecomastia in boys, which involves enlargement of breast tissue. The lawsuits generally claim that J&J was aware of the risk of this side effect, but understated the risk to doctors.

It is also the latest in a series of costly legal setbacks for J&J in a slew of lawsuits alleging injuries from products and other claims. In August, an Oklahoma judge ordered the company to pay $572 million for contributing to the state's opioid-addiction crisis.

Last year, a St. Louis jury found J&J should pay $4.69 billion in damages to 22 women and their families who blamed ovarian-cancer cases on use of the company's baby powder.

J&J has denied the allegations and is seeking to appeal the baby-powder and opioid decisions. Last week, J&J said it agreed to pay $20.4 million to settle lawsuits filed by two Ohio counties alleging the company helped spark the opioid epidemic; the company didn't admit liability.

When ruling on appeals, judges often reduce jury punitive-damage awards.

The latest verdict stems from a lawsuit filed by Nicholas Murray, who said his use of Risperdal between 2003 and 2008 caused gynecomastia. In 2015, a Philadelphia jury awarded Mr. Murray $1.75 million in damages, which a judge reduced to $680,000, but the judge had barred the jury from awarding punitive damages at that time.

An appeals court later overturned the judge's decision on punitive damages, clearing the way for the punitive-damages phase of the trial to start in September, ending with Tuesday's verdict.

J&J, based in New Brunswick, N.J., said in a statement Tuesday it will immediately move "to set aside this excessive and unfounded verdict." The company said the amount was "grossly disproportionate" to the initial compensatory award of $680,000, and it is confident the verdict will be overturned.

J&J said it was precluded from presenting a meaningful defense due to the court's exclusion of key evidence, and that the prescribing label for Risperdal properly outlined its risks.

Mr. Murray's lawyers, Thomas Kline and Jason Itkin, said in a statement that the jury "resoundingly told Johnson & Johnson that its actions were deliberate and malicious."

Risperdal, which treats schizophrenia, bipolar disorder and irritability associated with autism, was one of J&J's highest-selling products before losing its U.S. patent exclusivity in 2008.

Write to Peter Loftus at peter.loftus@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
04:55pJOHNSON & JOHNSON : Janssen Presents New Long-term Tremfya Data
02:06pJOHNSON & JOHNSON : to Pay $117 Million Over Surgical Device Marketing
01:07pJOHNSON & JOHNSON : J&J agrees to $117M settlement over pelvic mesh devices
11:46aJOHNSON & JOHNSON : Announces Quarterly Dividend for Fourth Quarter 2019
02:49aJOHNSON & JOHNSON : J&J Seeks $4 Billion Opioid Settlement
01:08aJOHNSON & JOHNSON : Jury seated in opioid case, but settlement talks go on
10/16JOHNSON & JOHNSON : J&J Offers $4 Billion Opioid Litigation Settlement
10/16Johnson & Johnson Shares Rise
10/16JOHNSON & JOHNSON : Genmab Announces Net Sales of DARZALEX for Third Quarter of ..
10/16Drug Firms In Talks To Settle Lawsuits -- WSJ
More news
Financials (USD)
Sales 2019 82 226 M
EBIT 2019 25 622 M
Net income 2019 19 665 M
Debt 2019 7 881 M
Yield 2019 2,76%
P/E ratio 2019 18,9x
P/E ratio 2020 17,7x
EV / Sales2019 4,47x
EV / Sales2020 4,19x
Capitalization 359 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 149,16  $
Last Close Price 136,17  $
Spread / Highest target 27,0%
Spread / Average Target 9,54%
Spread / Lowest Target -5,27%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.94%356 736
ROCHE HOLDING AG19.25%245 163
MERCK AND COMPANY10.52%216 224
PFIZER-16.75%200 998
NOVARTIS16.20%198 756
NOVO NORDISK AS19.22%122 115